Cellectis (NASDAQ:CLLS) Issues Quarterly Earnings Results, Beats Expectations By $0.08 EPS

Cellectis (NASDAQ:CLLS) released its quarterly earnings results on Monday. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.08, Zacks reports. The business had revenue of $7.55 million during the quarter, compared to analysts’ expectations of $11.04 million. Cellectis had a negative return on equity of 73.75% and a negative net margin of 89.51%.

Cellectis Price Performance

NASDAQ CLLS traded up $0.10 during midday trading on Wednesday, hitting $4.06. The company had a trading volume of 3,327 shares, compared to its average volume of 40,950. The company has a market capitalization of $406.88 million, a PE ratio of -6.05 and a beta of 2.94. The company has a current ratio of 1.62, a quick ratio of 1.62 and a debt-to-equity ratio of 0.98. The firm has a 50-day moving average price of $3.68 and a 200-day moving average price of $4.01. Cellectis has a twelve month low of $1.33 and a twelve month high of $5.48.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on CLLS. Citizens Jmp reaffirmed a “market outperform” rating and issued a $8.00 price objective on shares of Cellectis in a report on Tuesday, April 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cellectis in a report on Monday, April 20th. Finally, Jefferies Financial Group began coverage on Cellectis in a report on Tuesday, February 17th. They issued a “buy” rating and a $7.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $6.75.

Hedge Funds Weigh In On Cellectis

Several hedge funds and other institutional investors have recently modified their holdings of the business. Global Retirement Partners LLC bought a new position in shares of Cellectis in the 4th quarter valued at $34,000. Millennium Management LLC grew its position in Cellectis by 61.9% during the 3rd quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock worth $165,000 after acquiring an additional 22,080 shares during the last quarter. Virtu Financial LLC bought a new stake in Cellectis during the 3rd quarter worth $72,000. Acadian Asset Management LLC grew its position in Cellectis by 132.9% during the 1st quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 26,461 shares during the last quarter. Finally, Marshall Wace LLP grew its position in Cellectis by 1,610.3% during the 4th quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company’s stock worth $864,000 after acquiring an additional 168,038 shares during the last quarter. Institutional investors own 63.90% of the company’s stock.

About Cellectis

Cellectis is a clinical?stage biopharmaceutical company specializing in the development of gene?edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T?cell (CAR?T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off?the?shelf immunotherapies.